DERM
Journey Medical Corporation
There isn't enough reported data to score DERM yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
DERM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Unavailable | |
| Strong |
DERM's revenue and balance sheet are currently healthy, and its profitability is stable. There isn't enough data to rate its cash flow.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
DERM PE Valuation
DERM has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 15x next year's earnings.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
DERM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
DERM has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
DERM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.30 | — |
| Q3 2026 | -$0.18 | +$0.15 |
| Q2 2026 | -$0.22 | +$0.14 |
| Q1 2026 | -$0.37 | $0.00 |
| Q4 2025 | -$0.47 | +$0.25 |
| Q3 2023 | -$0.84 | +$2.61 |
| Q2 2023 | -$2.21 | +$1.83 |
| Q1 2023 | -$2.18 | +$2.73 |
| Q4 2022 | -$1.69 | +$3.11 |
DERM is still losing money, but far less than before: $0.18 per share over the past year, against $4.91 at its worst in early 2022.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over DERM on earnings quality, reporting a profit while its opponent remains loss making.
DERM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $19M | +7.6% |
| Q2 2026 | $18.5M | +23% |
| Q1 2026 | $16M | +21% |
| Q4 2025 | $16.1M | +18% |
| Q3 2025 | $17.6M | +21% |
| Q2 2025 | $15M | +1% |
| Q1 2025 | $13.1M | +0.8% |
| Q4 2024 | $13.6M | -11% |
DERM's revenue is recovering but still below its 2023 peak: $19M last quarter, up 7.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -2.8% | +5.9 points |
| Q2 2026 | 2.5% | +22 points |
| Q1 2026 | -9.3% | +16 points |
| Q4 2025 | -2.8% | -19 points |
| Q3 2025 | -8.7% | +11 points |
| Q2 2025 | -19% | +0.5 points |
| Q1 2025 | -25% | +52 points |
| Q4 2024 | 16% | +30 points |
DERM's operating margin was −2.8% last quarter, up 5.9 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over DERM on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over DERM on profitability, with a higher operating margin.
DERM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$3.4M | -$1.1M |
| Q2 2026 | -$1.7M | -$792K |
| Q1 2026 | $2.9M | +$5.7M |
| Q3 2023 | $18.7M | +$26M |
| Q2 2023 | $4M | +$7.3M |
| Q1 2023 | -$6M | -774% |
| Q2 2022 | -$3.3M | +$4.1M |
| Q1 2022 | $884K | -35% |
DERM has burned cash in most quarters: −$5M over the past year, against −$2M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over DERM in the latest year-over-year cash flow comparison.
DERM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.1% | +575K shares |
| 1 year | +12% | +3.1M shares |
| 3 years | +33% | +7M shares |
| 5 years | +206% | +18.9M shares |
| Available history | -48% | -26.4M shares |
DERM has 28M diluted shares, up 12% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q3 2019 | $163,999 |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over DERM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
DERM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2021 | -1.1x | Net Cash |
| Q4 2020 | 0.2x | Very low |
DERM has more cash than debt.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
DERM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.0 | Neutral |
| Stochastic | 7.6 | Oversold |
DERM's weekly RSI is 35 (neutral) and its Stochastic is 8 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
DERM PE vs Healthcare Sector
DERM has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
DERM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.38 | 18% below |
| 20 week MA | $6.38 | 31% below |
| 50 week MA | $6.65 | 34% below |
| 100 week MA | $6.59 | 33% below |
| 200 week MA | $5.14 | 15% below |
DERM is in a downtrend: it's below all five of its weekly moving averages, and 15% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over DERM on trend strength, trading above more of its moving averages.
DERM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $9.50 | $5.70 | -40% |
| 2022 | $5.70 | $1.18 | -79% |
| 2023 | $1.18 | $5.76 | +388% |
| 2024 | $5.76 | $4.17 | -28% |
| 2025 | $4.17 | $7.92 | +90% |
| 2026 YTD | $7.92 | $4.39 | -45% |
DERM's yearly returns have swung widely, from +388% in 2023 to −79% in 2022. It's down 45% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over DERM on returns for 2026, with the stronger performance.